Assessment of Safety, Tolerability, Systemic Exposure and Efficacy of GPB Cream in Adolescents With Severe Primary Hyperhidrosis

Dr. August Wolff GmbH & Co. KG Arzneimittel44 enrolled

Overview

The aim of this study is to evaluate the safety, tolerability and systemic exposure (in a subset of patients) of topical administration of 1% GPB in adolescents with severe primary axillary hyperhidrosis.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Primary Axillary Hyperhidrosis

Interventions

Glycopyrronium Bromide (GPB) CreamDRUG

Application of cream to each axilla

Eligibility

Sex: ALLMin age: 12 YearsMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Medical diagnosis of severe primary axillary hyperhidrosis with a PRHS score of ≥5 with symptoms for at least 3 months before Screening * At least 50 mg of sweat production in each axilla measured gravimetrically over a period of 5 minutes at room temperature along with a humidity consistent with the normal climate in that area (patients have to acclimatize to that room for at least 30 minutes before the measurement) * Adolescents of both sexes aged 12 to 17 years (until study completion) with a body mass index percentile ≥10 and ≤90 (according to Kromeyer-Hauschild et al 2001) * Local tolerability assessment (skin reaction) score = 0 Exclusion Criteria: * Secondary hyperhidrosis, ie, hyperhidrosis that is secondary to other underlying diseases such as (but not limited to) hyperthyroidism, lymphoma, and malaria * Previous surgical treatment of hyperhidrosis including sympathectomy, surgical debulking of the sweat glands, subcutaneous tissue curettage, ultrasonic surgery, microwave treatment (miraDry), or laser treatment * Botulinum toxin treatment for the treatment of axillary hyperhidrosis in the previous 4 months * Hypersensitivity to glycopyrrolate, or to any of the excipients of the investigational medicinal product (IMP)

Locations (1)

Dr. Michael Sebastian

Mahlow, Germany

Outcomes

Primary Outcomes

Number of patients with Adverse Drug Reaction during treatment

Time frame: Baseline to Day 57

Number of patients with a local tolerability assessment (skin reaction score) >0 during treatment

Time frame: Baseline to Day 57

Αbsolute change in GP plasma concentration from Baseline to Day 15

Time frame: Baseline to Day 15

Secondary Outcomes

Absolute change in logarithmic values of total sweat production assessed by GM from Baseline to Day 29

Time frame: Baseline to Day 29

Absolute change in logarithmic values of total sweat production assessed by GM from Baseline to Day 57

Time frame: Baseline to Day 57

Absolute change in logarithmic values of total sweat production assessed by GM from Day 29 to Day 57

Time frame: Day 29 to Day 57

Relative change in total sweat production assessed by GM from Baseline to Day 29 and Day 57

Time frame: Baseline to Day 29 and Day 57

Relative change in total sweat production assessed by GM from Day 29 to Day 57

Time frame: Day 29 to Day 57

Proportion of responders assessed by GM at Day 29 and Day 57

Time frame: Day 29 and Day 57

Absolute change in patient-rated hyperhidrosis severity (PRHS) score from Baseline to Day 29 and Day 57

The patient-rated hyperhidrosis severity (PRHS) score will be assessed by asking the following question: "How did you perceive your underarm sweating in the past 24 hours? Please rate it on a scale from 0 (no sweating at all) to 10 (worst sweating that you ever had)"

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Time frame: Baseline to Day 29 and Day 57

Absolute change in patient-rated hyperhidrosis severity (PRHS) score from Day 29 to Day 57

Time frame: Day 29 to Day 57

Absolute change in the Children's dermatology life quality index (CDLQI) score from Baseline to Day 29 and Day 57

The Children's dermatology life quality index (CDLQI) is a simple 10-question questionnaire that assesses the burden of hyperhidrosis. It is validated for children aged 5-16 years. The answers to the questions are generally scored on a 4-point scale: 'very much' = 3, 'quite a lot' = 2, 'only a little' = 1, 'not at all' or question unanswered = 0. The CDLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more impairment of the child's life is experienced.

Time frame: Baseline to Day 29 and Day 57

Absolute change in the Children's dermatology life quality index (CDLQI) score from Day 29 to Day 57

Time frame: Day 29 to Day 57

Absolute change in GP plasma concentration from Baseline to Day 8

Time frame: Baseline to Day 8

Absolute change in GP plasma concentration from Day 8 to Day 15

Time frame: Day 8 to Day 15

Frequency, severity, and relation of ADRs, SAEs, TEAEs, SUSARs, and discontinuations due to TEAEs

Time frame: Screening to 14 Days after End of Treatment

Local tolerability based on the skin reaction score

Local tolerability at the application sites will be assessed and evaluated by the investigator using a skin reaction score: 'No evidence of irritation' = 0, 'Minimal erythema, barely perceptible' = 1, 'Definite erythema, readily visible; minimal edema or minimal popular response' = 2, 'Erythema and papules' = 3, 'Definite edema' = 4, 'Erythema, edema, and papules' = 5, 'Vesicular eruption' = 6, 'Strong reaction spreading beyond test site' = 7, 'Folliculitis' = 8.

Time frame: Day 1, Day 29, Day 57/End of Treatment and 14 Days after Day 57/End of Treatment

Neurological assessment of anticholinergic effects by a 4-point scale

The occurrence of possible anticholinergic effects including dry mouth, dry eyes, blurred vision, red eyes, constipation, micturition disorder, drowsiness, and concentration difficulties is rated on a 4-point scale: 'severe intensity' = 3, 'moderate intensity' = 2, 'mild intensity' = 1, 'no evidence' = 0.

Time frame: 7 to 4 Days before Baseline, Day 15, Day 29, Day 43, Day 57/End of Treatment